Biomedal Life Science is devoted to the development and commercialization of products and services for life sciences research, and technology for industrial bioprocesses. Its own technology allowed the improvement of recombinant protein production.Biomedal Life Science also functions as a CRO (Contract Research Organization) and provides services and support to pharmaceutical or biotechnology companies.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Medical

FLAGSHIP PIONEERING ANNOUNCES THE MERGER OF TWO LEADING PROGRAMMABLE MEDICINE PLATFORMS TO FORM SAIL BIOMEDICINES

PR Newswire | October 25, 2023

news image

Flagship Pioneeringannounced the combination of Laronde and Senda Biosciences to launch Sail Biomedicines, a company pioneering the design and deployment of fully programmable medicines to transform patient care. Sail harnesses the power of first-in-category programmable payloads of Endless RNA™ (eRNA), first-in-category programmable nanoparticles, and emerging, proprietary...

Read More

Medical, Industry Outlook

DESIGN THERAPEUTICS TO PRESENT PRECLINICAL DATA ON ITS GENETAC™ SMALL MOLECULE, DT-168, FOR THE TREATMENT OF FUCHS ENDOTHELIAL CORNEAL DYSTROPHY

Globenewswire | April 25, 2023

news image

Design Therapeutics, Inc. a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that preclinical data for the company’s novel GeneTAC™ small molecule, DT-168, an eye drop being developed for the treatment of Fuchs endothelial corneal dystrophy (FECD), will be presented during an oral session at the Association for Research in Vision and Ophthalmology 2023 Annual Meeting (ARVO 2023), which is being held in New Orl...

Read More

Industrial Impact

ENTERIS BIOPHARMA COMPLETES MANUFACTURING FACILITY EXPANSION AND ANNOUNCES THE LAUNCH OF CDMO BUSINESS SEGMENT

Enteris BioPharma | May 04, 2021

news image

Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies and a wholly-owned subsidiary of SWK Holdings Corporation, announced today the expansion of its Boonton, NJ manufacturing facility and the launch of its CDMO business segment, which provides custom solutions for the formulation, growth, and manufacturing of pharmaceuticals. Enteris also offers bench to market facilities, such as the development, manufacturing, monit...

Read More

Cell and Gene Therapy

SOLVIAS TO PERFORM RELEASE TESTING ON WORLD'S FIRST CRISPR-BASED GENE-EDITING THERAPY

Solvias | January 23, 2024

news image

Solvias, a global provider of chemistry, manufacturing, and control (CMC) analytics, announced that it will perform analytical release testing services on the world's first CRISPR/Cas9 genome-edited cell therapy. The company has signed a long-term agreement with Vertex Pharmaceuticals for CASGEVY™ (exagamglogene autotemcel or exa-cel) which received U.S. Food & Drug Administration (FDA) approval for the treatment of sickle cell disease (SCD) in patients 12 years and older wit...

Read More
news image

Medical

FLAGSHIP PIONEERING ANNOUNCES THE MERGER OF TWO LEADING PROGRAMMABLE MEDICINE PLATFORMS TO FORM SAIL BIOMEDICINES

PR Newswire | October 25, 2023

Flagship Pioneeringannounced the combination of Laronde and Senda Biosciences to launch Sail Biomedicines, a company pioneering the design and deployment of fully programmable medicines to transform patient care. Sail harnesses the power of first-in-category programmable payloads of Endless RNA™ (eRNA), first-in-category programmable nanoparticles, and emerging, proprietary...

Read More
news image

Medical, Industry Outlook

DESIGN THERAPEUTICS TO PRESENT PRECLINICAL DATA ON ITS GENETAC™ SMALL MOLECULE, DT-168, FOR THE TREATMENT OF FUCHS ENDOTHELIAL CORNEAL DYSTROPHY

Globenewswire | April 25, 2023

Design Therapeutics, Inc. a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that preclinical data for the company’s novel GeneTAC™ small molecule, DT-168, an eye drop being developed for the treatment of Fuchs endothelial corneal dystrophy (FECD), will be presented during an oral session at the Association for Research in Vision and Ophthalmology 2023 Annual Meeting (ARVO 2023), which is being held in New Orl...

Read More
news image

Industrial Impact

ENTERIS BIOPHARMA COMPLETES MANUFACTURING FACILITY EXPANSION AND ANNOUNCES THE LAUNCH OF CDMO BUSINESS SEGMENT

Enteris BioPharma | May 04, 2021

Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies and a wholly-owned subsidiary of SWK Holdings Corporation, announced today the expansion of its Boonton, NJ manufacturing facility and the launch of its CDMO business segment, which provides custom solutions for the formulation, growth, and manufacturing of pharmaceuticals. Enteris also offers bench to market facilities, such as the development, manufacturing, monit...

Read More
news image

Cell and Gene Therapy

SOLVIAS TO PERFORM RELEASE TESTING ON WORLD'S FIRST CRISPR-BASED GENE-EDITING THERAPY

Solvias | January 23, 2024

Solvias, a global provider of chemistry, manufacturing, and control (CMC) analytics, announced that it will perform analytical release testing services on the world's first CRISPR/Cas9 genome-edited cell therapy. The company has signed a long-term agreement with Vertex Pharmaceuticals for CASGEVY™ (exagamglogene autotemcel or exa-cel) which received U.S. Food & Drug Administration (FDA) approval for the treatment of sickle cell disease (SCD) in patients 12 years and older wit...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us